S
Susumu Kobayashi
Researcher at Beth Israel Deaconess Medical Center
Publications - 648
Citations - 23408
Susumu Kobayashi is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Total synthesis & Epidermal growth factor receptor. The author has an hindex of 62, co-authored 629 publications receiving 21514 citations. Previous affiliations of Susumu Kobayashi include Chiba University & University of Tokyo.
Papers
More filters
Journal ArticleDOI
Clinical benefits of steroid therapy on surgical stress in patients with esophageal cancer
Hideaki Shimada,Takenori Ochiai,Shinichi Okazumi,Hisahiro Matsubara,Yoshihiro Nabeya,Yukimasa Miyazawa,Miwako Arima,Yutaka Funami,Hideki Hayashi,Akihiko Takeda,Yoshio Gunji,Takao Suzuki,Susumu Kobayashi +12 more
TL;DR: Perioperative steroid therapy was safe and effective for the inhibition of inflammatory mediators and the improvement of the postoperative clinical course of patients with esophageal cancer.
Journal ArticleDOI
Creation of novel chiral synthons with enzymes and applications to natural product synthesis. 15. Efficient introduction of chiral centers into cyclohexane ring
TL;DR: The chiral half-ester obtained by asymmetric hydrolysis of the symmetric diester 1 with pig liver esterase has been shown to be a versatile synthon for various chiral cyclohexane derivatives.
Journal ArticleDOI
Biological functions of a novel lipid mediator, cyclic phosphatidic acid
Kimiko Murakami-Murofushi,Ayako Uchiyama,Yuko Fujiwara,Tetsuyuki Kobayashi,Susumu Kobayashi,Mutsuko Mukai,Hiromu Murofushi,Gabor Tigyi +7 more
TL;DR: A novel bioactive lipid that was isolated originally from myxoamoebae of a true slime mold, Physarum polycephalum, and has now been detected in a wide range of organisms from slime molds to humans is focused on.
Journal ArticleDOI
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Norihiro Yamaguchi,Antonio R. Lucena-Araujo,Sohei Nakayama,Lorena Lobo de Figueiredo-Pontes,David A. Gonzalez,Hiroyuki Yasuda,Susumu Kobayashi,Daniel B. Costa +7 more
TL;DR: Activation of EGFR as a mechanism of resistance to crizotinib in preclinical models of ALK translocated NSCLC is identified, and the use of AlK plus EGFR TKIs could be explored for this important cohort of NSCLCs.
Journal ArticleDOI
β-catenin contributes to lung tumor development induced by EGFR mutations
Sohei Nakayama,Natasha J. Sng,Julian Carretero,Robert S. Welner,Yuichiro Hayashi,Mihoko Yamamoto,Alistair J. Tan,Norihiro Yamaguchi,Hiroyuki Yasuda,Danan Li,Kenzo Soejima,Ross A. Soo,Daniel B. Costa,Kwok-Kin Wong,Susumu Kobayashi +14 more
TL;DR: It is shown that β-Catenin is essential for development of EGFR-mutated lung cancers and that targeting the β-catenin pathway may provide novel strategies to prevent lung cancer development or overcome resistance to EGFR TKIs.